查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198259

唾液收集和诊断市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Saliva Collection and Diagnosis Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

唾液收集和诊断市场预计在预测期内（2022 年至 2027 年）以 10.1% 的复合年增长率增长。

由于人口中传染病病例的增加以及对基于自体唾液的非侵入性检测的偏好不断增加，COVID-19 对市场的增长产生了重大影响。 诊断 COVID-19 感染患者的需求日益增长，这为唾液收集和诊断市场创造了有利可图的机会。 例如，根据世界卫生组织 (WHO) 的数据，从 2022 年 1 月 17 日至 23 日，全球新发 COVID-19 病例数增加了 5%。 此外，市场参与者的举措也有助于市场的增长。 例如，2021年12月，Cotipharma在非洲推出了基于唾液的Omicron检测PCR检测。 该测试带有 CE 标誌，可以检测所有已知的 SARS-CoV-2 变体，包括 Omicron。 因此，预计 COVID-19 将对市场增长产生重大影响。

此外，全球人口中不断上升的传染病被认为是市场增长的主要驱动力之一。 根据世界卫生组织 (WHO) 的数据，到 2021 年，全球 60% 的人口将患有传染病。 此外，传染病每年导致超过 1700 万人死亡，这说明了全球传染病的负担。 越来越多的传染病患者正在推动对安全有效的诊断测试和产品的需求。 因此，唾液收集/诊断作为一种非侵入性诊断方法对患者筛查多种疾病起着重要作用。

此外，增加唾液收集和诊断产品的产品批准是可能促进市场增长的关键因素。 例如，2021 年 7 月，Hologic Inc. 的 HOLX optima SARS-COV-2 分子诊断测试获得欧盟 CE 标誌，用于唾液样本。

此外，公共机构的努力也在推动市场的增长。 例如，2022 年 8 月，澳大利亚通过免费的 DNA 唾液测试启动了世界上第一个针对癌症和心脏病风险的预防性 DNA 筛查计划。 这是澳大利亚莫纳什大学牵头的国家合作项目。 此外，利用可访问和非侵入性样本类型，市场参与者支持实验室使用库存唾液样本进行科学研究的举措可能对市场增长产生积极影响。 例如，2021 年 9 月，Thermo Fisher Scientific 推出了 Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit，用于安全收集唾液用于研究。 这些举措也有助于市场的增长。

因此，由于上述因素，市场有望在预测期内出现增长。 然而，收割设备的高成本可能会阻碍市场增长。

唾液采集/诊断市场趋势

预计在预测期内诊断实验室部分将占据主要市场份额

由于实验室间唾液收集和诊断的利用率不断提高，按应用划分的诊断实验室子细分市场预计将推动市场增长。 该领域的增长因素包括传染病和慢性病的增加、检测的便利性、医疗机构中独立和独立诊断实验室的增加以及熟练专业人员的可用性。

COVID-19 的突然爆发导致全球感染 COVID-19 疾病的人数激增，这增加了对唾液采集和诊断的需求。 诊断实验室在检测和诊断包括 COVID-19 在内的各种疾病方面发挥着重要作用，设备先进，结果迅速，因此，该领域有望在分析期间增长。

此外，随着癌症等慢性病患病率的增加，诊断实验室越来越多地使用非侵入性筛查方法。 例如，美国癌症协会的 2022 年统计数据估计，2022 年美国将诊断出约 54,000 例口腔或口咽癌新病例。 采集唾液的诊断方法以其准确率高、痛苦小等优点被广泛应用于诊断机构的癌症诊断。

新产品的发布也在推动这一细分市场的增长。 例如，在 2022 年 6 月，Goodbody Health 推出了四项唾液测试，通过查看您的基因来确定您在未来 10 年内患癌症或心脏病的风险。 预计此类发布将在未来几年推动该细分市场的增长。

因此，由于上述因素，市场有望在预测期内出现增长。

预计北美将占据很大的市场份额，预计在预测期内也会如此

由于传染病的流行、对唾液检测的日益偏好以及市场参与者推出新产品，预计北美将占据很大的市场份额。

在美国，慢性病患病率的上升导致对唾液采集和诊断产品的需求增加。 据美国癌症协会统计，2022 年美国估计有 38,700 名男性和 15,300 名女性患有口腔癌和咽癌。 同样，根据 MedAlertHelp 发布的统计数据，到 2022 年，每年将有大约 5% 到 20% 的美国人被诊断出患有流感。 此外，根据美国疾病控制与预防中心 2021 年 10 月公布的数据，2019-20 赛季将有 3500 万例与流感相关的疾病，38 万例与流感相关的住院治疗，2019 年全年有 2 万例与流感相关的疾病。 -2020 季节。报告了相关死亡和 1600 万次与流感相关的咨询。 这种日益增加的疾病负担产生了对唾液收集和诊断的需求，推动了该地区的市场增长。

此外，产品发布预计将推动该地区的市场增长。 例如，2022 年 8 月，Viome Life Sciences 推出了 CancerDetect，这是一种使用 mRNA 技术和人工智能平台的口腔癌和咽癌诊断测试。 此外，2021 年 9 月，Thermo Fisher Scientific 将推出 SpeciMax Stabilized Saliva Collection Kit，用于安全收集唾液用于研究。 该试剂盒将病毒核酸保存在可灭活常见呼吸道病毒的无害稳定溶液中。

因此，由于上述因素，预计该地区的研究市场将在预测期内增长。

唾液采集和诊断市场竞争者分析

唾液采集和诊断市场竞争适中，由几家大型企业组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 目前主导市场的公司有 Thermo Fisher Scientific、Neogen Corporation、Abbott、Sarstedt AG &Co.KG、Autogen, Inc、Oasis Diagnostics、Porex、Salimetrics, LLC、Takara Bio, Inc、Arcis Bio、Orasure Technologies 等。 .

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 传染病因人口增长而增加
    • 更多地使用无创唾液检测来代替血液检测
  • 市场製约因素
    • 采样设备成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（金额基础：百万美元）

  • 按采样点
    • 腮腺取样
    • 颌下腺取样
    • 小唾液腺收集
  • 通过使用
    • 诊断实验室
    • 取证
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Thermo Fisher Scientific
    • Neogen Corporation
    • Abbott
    • Sarstedt AG and Co.KG
    • Autogen Inc
    • Oasis Diagnostics
    • Porex
    • Salimetrics, LLC
    • Takara Bio, Inc
    • Arcis Bio
    • Orasure Technologies

第7章 市场机会与今后动向

简介目录
Product Code: 90464

The saliva collection and diagnosis market are projected to register a CAGR of 10.1% during the forecast period (2022-2027).

COVID-19 has had a significant impact on the growth of the market, owing to the rising cases of infectious diseases among people and an increased preference for non-invasive and self-saliva-based tests. The increase in the need to diagnose COVID-19 infected patients created lucrative opportunities for the saliva collection and diagnosis market. For instance, according to the World Health Organization (WHO), in January 2022, the number of new COVID-19 cases increased by 5% across the globe from January 17th to January 23rd, 2022. Additionally, initiatives taken by the market players also contributed to the growth of the market. For instance, in December 2021, Cotipharma launched a saliva-based Omicron detecting PCR test in Africa. This test is CE-marked and can detect all known variants of SARS-CoV-2, including Omicron. Thus, COVID-19 is expected to have a significant impact on the growth of the market.

Furthermore, the increasing prevalence of infectious diseases among people across the globe is assumed to be one of the major driving factors for market growth. According to the World Health Organization (WHO), in 2021, 60% of the global population suffered from infectious diseases. The report also stated that infectious diseases kill over 17 million people a year, which illustrates the global burden of infectious diseases. The rise in the number of infectious cases has led to the demand for safe and effective diagnostic tests and products. Hence, saliva collection and diagnosis play a major role as a non-invasive diagnostic method for screening patients for several diseases.

Moreover, the increase in product approvals for saliva collection and diagnostic products is a significant factor likely to augment the market's growth. For instance, in July 2021, Hologic Inc.'s HOLX optima SARS-COV-2 molecular diagnostic test received CE marking by the European Union for its use with a saliva sample.

Additionally, the initiatives taken by the public authorities are also propelling the growth of the market. For instance, in August 2022, Australia launched one of the world's first preventative DNA screening programs for cancer and heart disease risk through free DNA saliva tests. It is a nationally collaborative project, led by Australia's Monash University. Furthermore, the initiatives taken by market players to support labs in conducting scientific studies using banked saliva samples, taking advantage of a sample type that is easy to access and non-invasive, are expected to have a positive impact on the growth of the market. For instance, in September 2021, Thermo Fisher Scientific launched the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit, which is designed to safely collect saliva for research. Such initiatives also contribute to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, the high cost of collection devices may impede the growth of the market.

Saliva Collection & Diagnosis Market Trends

The Diagnostic Laboratories Segment is Expected to Hold a Major Market Share Over the Forecast Period

The diagnostic laboratories sub-segment by application is expected to drive the market's growth due to the increasing usage of saliva collection and diagnosis across laboratories. Factors contributing to the growth of the segment include the increasing prevalence of infectious and chronic diseases; ease of conduct; the growing number of standalone diagnostic laboratories as well as in-built diagnostic labs within healthcare settings; and the availability of skilled professionals.

The sudden outbreak of COVID-19 has increased the demand for saliva collection and diagnosis due to the surge in the number of infectious cases of COVID-19 disease across the world. Diagnostic laboratories play a crucial role in testing and diagnosing patients with COVID-19 and various other diseases owing to advanced equipment and quicker results, as a result of which, the segment is expected to project growth over the analysis period.

Moreover, the rising prevalence of chronic diseases such as cancer among people has led to the increasing use of non-invasive screening methods in diagnostic laboratories. For instance, the American Cancer Society's 2022 statistics estimated that about 54,000 new cases of the oral cavity or oropharyngeal cancer will be diagnosed in 2022 in the United States. Saliva collection and diagnosis is widely used in cancer diagnosis in diagnostic laboratories owing to its accuracy and painless procedure.

The launch of new products is also propelling the growth of the market segment. For instance, in June 2022, Goodbody Health Inc. launched four saliva tests that can determine a person's risk of getting cancer or heart disease over ten years via looking at genetics. Such launches are expected to propel the growth of the segment over the coming years.

Thus, owing to the abovementioned factors, the market segment is expected to project growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America is expected to hold a significant share in the market owing to the increasing prevalence of infectious diseases, growing preference for saliva tests, and the launch of newer products by the market players and others.

The increasing prevalence of chronic diseases in the United States contributes to the growing demand for saliva collection and diagnosis products. According to the American Cancer Society, 2022 statistics, it was estimated that in the United States there are about 38,700 males and 15,300 females living with oral and pharynx cancer. Similarly, according to statistics published by MedAlertHelp, in 2022, about 5% to 20% of Americans are diagnosed with influenza every year. Furthermore, according to the data published by the Centers for Disease Control and Prevention in October 2021, overall, 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits were reported in the 2019-2020 season. Such a growing burden of disease is creating demand for saliva collection and diagnosis, thus driving the growth of the market in the region.

Moreover, the launch of products is expected to drive the growth of the regional market. For instance, in August 2022, Viome Life Sciences launched CancerDetect, a diagnostic test for oral and throat cancer that uses mRNA technology and an AI-powered platform. Additionally, in September 2021, Thermo Fisher Scientific launched the SpeciMax Stabilized Saliva Collection Kit, which is designed to safely collect saliva for research. This kit preserves viral nucleic acids in a non-hazardous stabilization solution that inactivates common respiratory viruses.

Thus, owing to the abovementioned factors, the studied market in the region is expected to grow over the forecast period.

Saliva Collection & Diagnosis Market Competitor Analysis

The saliva collection and diagnosis market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Thermo Fisher Scientific, Neogen Corporation, Abbott, Sarstedt AG & Co.KG, Autogen, Inc., Oasis Diagnostics, Porex, Salimetrics, LLC, Takara Bio, Inc., Arcis Bio, Orasure Technologies, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Infectious Diseases Among the Population
    • 4.2.2 Rising Application of Non- Invasive Saliva testing as a Replacement of Blood Testing
  • 4.3 Market Restraints
    • 4.3.1 High Costs of Collection Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value -USD million)

  • 5.1 By Site of Collection
    • 5.1.1 Parotid Gland Collection
    • 5.1.2 Submandibular collection
    • 5.1.3 Minor Salivary Glands Collection
  • 5.2 By Application
    • 5.2.1 Diagnostic Laboratories
    • 5.2.2 Forensics
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 Neogen Corporation
    • 6.1.3 Abbott
    • 6.1.4 Sarstedt AG and Co.KG
    • 6.1.5 Autogen Inc
    • 6.1.6 Oasis Diagnostics
    • 6.1.7 Porex
    • 6.1.8 Salimetrics, LLC
    • 6.1.9 Takara Bio, Inc
    • 6.1.10 Arcis Bio
    • 6.1.11 Orasure Technologies

7 MARKET OPPORTUNITIES AND FUTURE TRENDS